lundi 24 août 2026
RechercherExplore
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Press releaseGlobeNewswire· March 3, 2026

AI in Genomics Market Research and Global Forecast Report 2026-2040 - Machine Learning-Driven Drug Discovery and Strategic Tech-Pharma Collaborations Fuel Growth

View original at globenewswire.com
AI in Genomics Market Research and Global Forecast Report 2026-2040 - Machine Learning-Driven Drug Discovery and Strategic Tech-Pharma Collaborations Fuel Growth Dublin, March 03, 2026 (GLOBE NEWSWIRE) -- The "AI in Genomics Market, till 2040: Distribution by Type of Component, Type of Technology, Type of Functionality…
Opening lines of the source · GlobeNewswire · short snapshot — read the full document at the original

Ce que nous avons tiré de cette source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • The rapid increase in genomic data generated by next-generation sequencing technologies has created a strong demand for AI-based tools capable of managing and analyzing complex datasets

    80% confidence
  • The AI in genomics market will grow at a CAGR of 43.75% during the forecast period till 2040

    80% confidence
  • Machine learning algorithms are enabling faster identification of genetic patterns, disease prediction, and drug target discovery, thereby significantly reducing both cost and time in research and development

    80% confidence
  • The global AI in genomics market size is estimated to grow from USD 1.97 billion in 2026 to USD 317.4 billion by 2040

    80% confidence
  • Drug development has traditionally been a lengthy and costly process, often taking several years and substantial investment, but AI-driven tools now enable rapid analysis of vast biomedical datasets

    80% confidence
  • The AI in genomics market faces several critical challenges including data quality and standardization issues, data privacy and compliance concerns, high computational costs, limited availability of skilled AI professionals, and lack of model interpretability

    80% confidence
  • AI algorithms can predict molecular interactions, optimize lead compounds, and identify potential drug candidates with higher precision

    80% confidence
  • The integration of AI into drug discovery and genomics is reshaping the healthcare landscape, expediting innovation, and advancing the global shift toward precision medicine

    80% confidence
  • The market for AI in genomics is expected to grow significantly due to the massive increase in genomic data from next-generation sequencing technologies, which outpaces traditional analysis methods and requires AI's pattern recognition capabilities

    80% confidence
  • Artificial intelligence is transforming the field of genomics by processing huge datasets from DNA sequencing to reveal insights that conventional techniques overlook

    80% confidence

Cité dans ces articles de Via News

Ce que nous savons · l'intelligence derrière cette page
En direct du substrat
Ce que nous observons
AI Leadership Exodus Rattles Investor Confidence Amid Capex Boom
High-profile departures at top AI labs — Brad Lightcap's exit from OpenAI and an unnamed researcher's departure from Alphabet/Google that triggered a share-price drop — are surfacing talent retention as a market risk factor even as hyperscalers pour record capital into AI infrastructure. The reaction shows investors treating key-person risk at frontier AI labs as material to valuation, a new fragility layered onto an otherwise bullish AI-driven capex cycle.
Notre lecture des données ›
Signaux que nous suivons
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Tendances que nous surveillons ›
Là où les sources divergent
Broadcom Inc.
Both facts report EPS for Broadcom Inc. for the same fiscal period (Q1 2026) observed on the same date (2026-02-01). However, they report conflicting values: 1.5 USD per share vs 2.05 USD per share. This is a 37% difference for the identical metric and time period, not a value change over time.
Nous signalons les conflits ouvertement ›
Vérifié récemment
Vérifié avec la source d'origine
4,978
faits reliés à leur source — et nous signalons ceux qui ne tiennent pas.
101 entités suivies4,978 faits vérifiés avec la source5,251 documents sources archivés
Interrogez ces données → isubstrate.com